M.B.A, CEO, Ariel Precision Medicine
Ms. Gibson is CEO and Chair of Ariel Precision Medicine which is positioned as the solution for early targeted management of complex chronic disorders, starting with pancreatic diseases. She has lead the development, clinical validation and commercial launch of Ariel’s first product, PancreasDx®, and a cloud based digital health platform. Ms. Gibson has focused on working with multiple stakeholders including establishing partnerships with National Pancreas Foundation and pharmaceutical companies. Prior to co-founding Ariel, Ms. Gibson worked with Purdue Pharma in Sales and Medical Marketing after earning National Product leader in 2012. Prior to Purdue she worked in the biotechnology field with Gene Wiz Inc. until 2007 when she joined Shionogi Pharmaceuticals Inc. Before entering industry, she worked in clinical care as a paramedic and published GI research. Ms. Gibson received her executive MBA from Liberty University after earning a Bachelor of Science in Emergency Medicine from the University of Pittsburgh.
Presentation Title and Company Description
Clinical Dx Showcase: Genomic Solutions for Complex Chronic Disease
Ariel Precision Medicine provides genetic testing and decision support tools for clinicians treating patients with complex chronic diseases. By integrating genetics with environmental and modifying factors, Ariel models disease mechanisms, course, and trajectory enabling early diagnosis, prognosis and targeted management.